Ketamine Bladder Is Affecting Children as Young as 13
🧪 Is It Actually Ketamine?
Testing can't make ketamine safe for your bladder, but it can tell you whether what you have behaves like ketamine at all. The Ketamine Spot Kit Package uses four reagents to screen your sample before you take it.
Get the Ketamine Spot Kit Package →Children as young as 13 are being treated for serious urinary damage caused by sustained ketamine use.
A specialist clinic at Alder Hey Children’s Hospital in Liverpool received more than 100 referrals after opening in May 2025. An analysis of its first 60 patients found an average age of just 14.5, with ketamine use often beginning around age 13.
The findings show how quickly ketamine bladder can become a serious health problem, particularly when frequent use and early symptoms go unrecognized.
In This Article
📋 The Alder Hey Findings at a Glance
- Clinic opened: May 2025, Alder Hey Children’s Hospital, Liverpool
- Referrals: More than 100
- Patients analyzed: First 60
- Ketamine use often began: Around age 13
- Emotional trauma in childhood: 72%
- Discharged after stopping ketamine: 12 of 60
What Is Ketamine Bladder?
Ketamine bladder is the common name for ketamine-induced uropathy, a condition that can affect the bladder, ureters and kidneys.
Ketamine and its metabolites are eliminated through urine. With repeated exposure, they can damage the bladder lining and contribute to inflammation, ulceration, and scarring.
Symptoms can include:
- Needing to urinate more frequently
- Sudden or uncontrollable urinary urgency
- Pain or burning while urinating
- Bladder or pelvic pain
- Blood in the urine
- Incontinence or bed-wetting
- Abdominal pain sometimes described as “K cramps”
As the condition progresses, the bladder may become smaller and less able to hold urine. Severe cases can cause kidney damage or require major surgery.
The Average Patient Was Only 14
The Alder Hey clinic analyzed information from its first 60 patients. More than 70% came from some of England’s most economically deprived communities, and 72% had experienced emotional trauma during childhood.
Approximately 27% had autism, ADHD or both, while one in five had experience within the care system. Half reported using other substances alongside ketamine.
This highlights why effective care must consider the person and circumstances behind the diagnosis, rather than treating bladder damage as an isolated medical problem.
Clinicians at Alder Hey use a nonjudgmental approach designed to help young people discuss their substance use honestly and access appropriate support.
Ketamine Can Create a Cycle of Pain and Continued Use
Some young people reportedly began using ketamine to relieve the pain caused by their existing bladder damage.
Because ketamine is an anesthetic, it may temporarily reduce discomfort. Continuing to use it can then expose the urinary system to more ketamine and its metabolites, potentially worsening the underlying injury.
This creates a cycle in which the substance contributing to the pain is also used to escape it.
Stopping ketamine can lead to improvement, particularly when the condition is identified early. Twelve of the clinic’s first 60 patients were discharged after stopping ketamine and experiencing improved symptoms. Advanced damage, however, may not be completely reversible.
Know What You Have Before You Take It
Morris, Mecke, Liebermann, and Froehde reagents work together to show whether a sample behaves like ketamine or points to something else.
Get the Ketamine Spot Kit Package →Drug Checking Cannot Prevent Ketamine Bladder.
A correctly identified sample of ketamine can still damage the urinary system. Drug checking cannot determine whether someone will develop ketamine bladder or establish a safe frequency of use.
It can address a different risk: whether a substance sold as ketamine contains ketamine at all.
The Ketamine Spot Kit Package uses multiple reagent reactions to evaluate whether a sample behaves consistently with ketamine. Results can be compared with lab-verified reaction videos in the free Transparency Harm Reduction App.
⚠️ Know the Limits: Reagent testing cannot confirm a substance’s identity, determine its purity, or rule out every additional compound. For more comprehensive identification, mail-in laboratory testing can analyze the compounds detected in a submitted sample.
Anyone learning how to test ketamine should follow the complete testing instructions and use multiple reagents rather than relying on one reaction.
The Ketamine Testing Order:
- Morris Test: Primary reagent for ketamine (Get Morris Kit)
- Mecke, Liebermann & Froehde: Follow-up reagents that help rule out look-alikes such as cathinones
- Compare Your Results: Match reactions against lab-verified videos in the Transparency Harm Reduction App or the Reaction Video Library
- Lab Analysis (Most Comprehensive): Mail-in testing through Transparency Testing
Remember: A sample that tests as ketamine can still damage your bladder. Testing answers what you have, not whether your use is safe.
Consistent Dosing Can Make Ketamine Use Easier to Track
Testing a substance and measuring your dose answer different questions. Drug checking provides information about what a sample may contain. Consistent measurement can help someone understand how much they are taking and how frequently they are redosing.
After testing, SprayPack can turn a correctly prepared ketamine solution into measured nasal sprays. When the solution’s concentration and the volume delivered per spray are known, it offers a more consistent way to measure and track intake than estimating differently sized lines.
That matters because ketamine-related urinary symptoms are associated with higher doses and more frequent use. Knowing the approximate dose per spray may make it easier to monitor redosing and cumulative consumption.
⚠️ Important: SprayPack does not prevent ketamine bladder, establish a safe ketamine dose, or make frequent use safe.
Early Ketamine Bladder Symptoms Should Not Be Ignored
Needing to urinate frequently, waking repeatedly during the night, experiencing bladder pain, or noticing blood in the urine are not symptoms to simply push through.
🚨 If You Have Symptoms: Anyone experiencing possible ketamine bladder symptoms should stop using ketamine and seek medical care. Being honest with a healthcare provider about ketamine use can help them investigate the correct cause and recommend appropriate treatment.
The Alder Hey findings show that serious urinary damage can develop in extremely young people after relatively short periods of sustained use. They also show that early intervention and appropriate support can make a meaningful difference.
Drug checking and dose tracking cannot eliminate ketamine’s urinary risks. They can reduce uncertainty around what someone has and how much they are taking. Recognizing symptoms and responding early remain essential.
Reduce the Uncertainty. Test First.
From four-reagent spot kits to measured nasal spray dosing, find the tools that help you know what you have and how much you're taking.
Explore Ketamine Harm-Reduction Tools →50-100 uses per reagent | Ships discreetly | Results in minutes
Related Resources
Learn more about testing ketamine and reducing risk:
- How to Test Ketamine – Reagent colors, testing order, and what each result means
- Ketamine Spot Kit Package – Morris, Mecke, Liebermann, and Froehde in one package
- All Ketamine Test Kits – Single reagents, packages, and SprayPack
- Reaction Video Library – Watch real-time reagent reactions to compare with your tests
- Transparency Harm Reduction App – Free lab-verified reaction videos
- Transparency Testing Lab Services – Mail-in laboratory analysis
- Our Types of Test Kits – Understanding the different testing methods available
Sources
- The Guardian — Andrew Gregory, “Children as young as 13 being referred to UK hospital suffering from ‘ketamine bladder’,” September 22, 2026: https://www.theguardian.com/society/2026/sep/22/liverpool-alder-hey-hospital-rise-children-ketamine-bladder-addiction
- Alder Hey Children’s NHS Foundation Trust — First-year findings from the ketamine-induced uropathy clinic (with Lancaster University; published in Archives of Disease in Childhood), September 2026: https://adc.bmj.com/content/early/2026/09/15/archdischild-2026-330727
